Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis

被引:18
作者
vanderPijl, JW
Srivastava, N
Denouel, J
Burggraaf, J
Schoemaker, RC
vanderWoude, FJ
Cohen, AF
机构
[1] CTR HUMAN DRUG RES, NL-2333 CL LEIDEN, NETHERLANDS
[2] LABS SANDOZ, CTR RECH PHARMACEUT, UNITE PHARMACOCINET, F-92506 RUEIL MALMAISON, FRANCE
关键词
D O I
10.1097/00007890-199608270-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cyclosporine (CsA) is an immunosuppressive drug requiring dose individualization and regular control due to its highly variable pharmacokinetics. Since gastroparesis may influence the absorption of CsA, a randomized cross-over study was performed to assess the pharmacokinetics and tolerability of a novel microemulsion CsA formulation in comparison with the standard CsA dosage form in six stable pancreas-kidney transplant recipients with scintigraphically proven gastroparesis. The absorption of CsA was investigated during three 2-hr study days during each treatment period, and a full pharmacokinetic profile was done for each formulation. No adverse events or differences in tolerability/safety parameters between the treatments were found. The average AUC(0-->2 hp) was 150% higher after the novel formulation, The coefficient of variation in AUC(0-->2 hr) for both formulations was comparable (37% after the microemulsion and 40% after the standard formulation). The median time at which blood CsA levels exceeded the preceding trough level by 20% was 30 min (range: 29-182 min) after the microemulsion and 90 min (range: 30->718 min) after the standard formulation. With approximately the same average dose, the AUC(tau)(ss) after the microemulsion was 81% higher than the standard formulation, while predose and 12-hr trough levels were similar. The average maximal CsA plasma level after the microemulsion was 396 ng/ml (95%CI: 71-722 ng/ml) higher than after the standard formulation. The median time at which the highest blood levels were observed was 90 min (range: 62-208 min) after the microemulsion and 225 min (range: 150->718 min) after the standard formulation. The time profiles of the CsA metabolites followed those of the parent compound. The microemulsion resulted in a higher systemic exposure to CsA than the standard formulation in pancreas-kidney transplant patients with diabetic gastroparesis, but substantial variability in blood concentrations remained.
引用
收藏
页码:456 / 462
页数:7
相关论文
共 19 条
[11]   THE RELATIONSHIP BETWEEN CYCLOSPORINE PHARMACOKINETIC PARAMETERS AND SUBSEQUENT ACUTE REJECTION IN RENAL-TRANSPLANT RECIPIENTS [J].
KASISKE, BL ;
HEIMDUTHOY, K ;
RAO, KV ;
AWNI, WM .
TRANSPLANTATION, 1988, 46 (05) :716-722
[12]  
KEOWN PA, 1995, 14 ANN M AM SOC TRAN, P74
[13]  
KOVARIK JM, 1994, TRANSPLANTATION, V58, P658
[14]  
LANG J, 1989, CLIN TRANSPLANT, V3, P1
[15]  
LEMAIRE M, 1990, TRANSPLANT P, V22, P1110
[16]   INTRAINDIVIDUAL VARIABILITY IN THE RELATIVE SYSTEMIC AVAILABILITY OF CYCLOSPORIN AFTER ORAL DOSING [J].
LINDHOLM, A ;
HENRICSSON, S ;
LIND, M ;
DAHLQVIST, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :461-464
[17]  
MERKUS JWS, 1992, TRANSPLANT INT, V5, pS17
[18]   PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL-ALLOGRAFT RECIPIENTS - A CONCENTRATION-CONTROLLED COMPARISON WITH THE COMMERCIAL FORMULATION [J].
MUELLER, EA ;
KOVARIK, JM ;
VANBREE, JB ;
LISON, AE ;
KUTZ, K .
TRANSPLANTATION, 1994, 57 (08) :1178-1182
[19]  
SCHROEDER TJ, 1995, TRANSPLANT P, V27, P837